Singapore lender, ME investors launch Islamic bank

May 7, 2007 10:29


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Singapore's DBS Group Holdings Ltd. and a group of Middle East investors on Monday launched the city-state's first Islamic bank, which will focus on commercial banking, corporate finance, capital markets and private banking services. The Islamic Bank of Asia will have an initial paid-up capital of US$418 million, but this will rise to about US$500 million in the coming weeks after a second round of fundraising with investors from Gulf Cooperation Council, or GCC, countries, DBS said in a statement. DBS, Southeast Asia's largest bank by assets, has an initial 60 percent stake in the Islamic bank after contributing US$250 million to its startup capital, but this will fall to 50 percent following the second capital raising. The bank will be based in Singapore and start operations this month.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection